I believe GlaxoSmithKline (LSE: GSK) is one of the markets most undervalued and under-appreciated stocks. Over the past year,the company has gone from a business struggling to grow, to projected earnings per share growth of 30% this year and 10% for 2017. If Glaxo hits these growth targets, the firms earnings per share will hit a level not seen since 2012.
However, despite this projected growth, shares in Glaxo are only trading at a forward P/E multiple of 15.1, falling to 13.8 for 2017. When you consider the fact that shares in other highly defensive companies such as Unilever and Reckitt Benckiserare trading at forward price-to-earnings multiples of around 20, Glaxos shares look severelyundervalued.
On top of Glaxos depressed valuation, the shares also support a dividend yield of 5.2%, compared to the market average of around 3%. Over the past few years, City analysts have expressed caution about the sustainability of Glaxos dividend payout as earnings per share have declined and the companys dividend cover slipped below one. But now the 80p per share payout is covered by earnings, allaying any payout concerns.
This year City forecasts suggest the payout will be covered 1.2 times by earnings per share and next year the payout cover is projected to rise to 1.4.
On the face of it, Glaxos shares look like a steal, but theres a reason why the shares have lost nearly 10% of their value over the past three months.
The market is worried about the pharmaceutical sectors growth prospects. Drug pricing was a hot issue in the US election, and now theres growing concern that regulators will act to control drug prices.
For some companies, a move to control drug prices will be devastating as this has been a key revenue driver over the past few years. For Glaxo this wont be such an issue. The company is growing organically as its pipeline of treatments under development begins to yield results. Whats more, the groups consumer healthcare division provides a stream of predictable income forGlaxo, which will grow slowly-but-steadily as the worlds population expands.
In a nutshell, while there are concerns surrounding Glaxos growth outlook, the company is proving doubters wrong. Even though earnings have received a boost from the devaluation of sterling since Brexit, at constant exchangerates Glaxos sales expanded 7% for the nine months to the end of September and operating profit grew 14% as new products hit the market.
So overall, shares in Glaxo are cheap relative to the companys projected growth and offer a market-beating dividend yield. Further, while there have been some concerns about Glaxos outlook, the company is still pushing ahead and organic growth looks set to continue for some time. As the company allays concerns about its growth outlook over the next 12 months, the market should begin to give Glaxo the valuation it deserves.
Looking for dividends?
If you’re looking for dividend champions to jump-start your portfolio’s income, I strongly recommend you check outthis special report, which gives a rundown of what I believe is one of the hottest dividend stocks in London today.
The exclusive report entitled A Top Income Share looks at a hidden FTSE giant that’s already an income champion but is also investing for growth and these ambitious expansion plans should power dividends through the roof in the years ahead.
To discover more justclick here and enjoy this exclusive wealth report.It’s 100% free and comes with no obligation.
Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Unilever. The Motley Fool UK has recommended Reckitt Benckiser. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.